We’re developing solutions to improve detection and characterization of cancer. Our three transformative technologies, NexGenAbler™, PointSuppressor™, and MethylMarker™ deliver orders of magnitude improvements to sensitivity and scalability of cell-free DNA-based liquid biopsy to enable effective, non-invasive cancer screening and monitoring.